DiapoCare: Marketed product limiting dermatitis

Jon D. Laman

DiapoCare: Marketed product limiting dermatitis

Translational Immunology Groningen (TRIGR)

Research output: Non-textual form › Digital or Visual Products › Academic

Abstract

Development and market introduction of protease inhibitors for topical cream application against skin inflammation. Clinical indications include: diaper dermatitis in babies, stoma patients, incontinence, congenital defects of the colon, Crohn’s disease, and cancer treatment side effects. Original scientific concept developed by Dr. J.G. van Embden, L. van Lieshout (Bsc) and J.D. Laman. Longstanding collaboration with the cooperation AVEBE (Veendam, Groningen) providing protease inhibitors from protein fraction of starch potatoes. The launching company is Eurodrug B.V. (Den Haag) with a cream for diaper dermatitis in healthy infants. This product called Diapocare is now marketed in the entire European Community, and 13 other countries including Thailand, Singapore and Hong Kong.

Eurodrug is providing Diapocare also in a compassionate use program for patients, including at UMCG (Depts. Dermatology and Gastroenterology). Eurodrug is currently developing this approach into a medical device for marketing in Europe and the USA. Medical Device Class I status was granted September 2020.

Original language	English
Media of output	Web
Publication status	Published - 2020

Handle.net

Persistent link

Cite this

@misc{2d6213f75ef3404faf85ddbedd039727,

title = "DiapoCare: Marketed product limiting dermatitis",

abstract = "Development and market introduction of protease inhibitors for topical cream application against skin inflammation. Clinical indications include: diaper dermatitis in babies, stoma patients, incontinence, congenital defects of the colon, Crohn{\textquoteright}s disease, and cancer treatment side effects. Original scientific concept developed by Dr. J.G. van Embden, L. van Lieshout (Bsc) and J.D. Laman. Longstanding collaboration with the cooperation AVEBE (Veendam, Groningen) providing protease inhibitors from protein fraction of starch potatoes. The launching company is Eurodrug B.V. (Den Haag) with a cream for diaper dermatitis in healthy infants. This product called Diapocare is now marketed in the entire European Community, and 13 other countries including Thailand, Singapore and Hong Kong.Eurodrug is providing Diapocare also in a compassionate use program for patients, including at UMCG (Depts. Dermatology and Gastroenterology). Eurodrug is currently developing this approach into a medical device for marketing in Europe and the USA. Medical Device Class I status was granted September 2020.",

author = "Laman, {Jon D.}",

year = "2020",

language = "English",

}

TY - ADVS

T1 - DiapoCare: Marketed product limiting dermatitis

A2 - Laman, Jon D.

PY - 2020

Y1 - 2020

N2 - Development and market introduction of protease inhibitors for topical cream application against skin inflammation. Clinical indications include: diaper dermatitis in babies, stoma patients, incontinence, congenital defects of the colon, Crohn’s disease, and cancer treatment side effects. Original scientific concept developed by Dr. J.G. van Embden, L. van Lieshout (Bsc) and J.D. Laman. Longstanding collaboration with the cooperation AVEBE (Veendam, Groningen) providing protease inhibitors from protein fraction of starch potatoes. The launching company is Eurodrug B.V. (Den Haag) with a cream for diaper dermatitis in healthy infants. This product called Diapocare is now marketed in the entire European Community, and 13 other countries including Thailand, Singapore and Hong Kong.Eurodrug is providing Diapocare also in a compassionate use program for patients, including at UMCG (Depts. Dermatology and Gastroenterology). Eurodrug is currently developing this approach into a medical device for marketing in Europe and the USA. Medical Device Class I status was granted September 2020.

AB - Development and market introduction of protease inhibitors for topical cream application against skin inflammation. Clinical indications include: diaper dermatitis in babies, stoma patients, incontinence, congenital defects of the colon, Crohn’s disease, and cancer treatment side effects. Original scientific concept developed by Dr. J.G. van Embden, L. van Lieshout (Bsc) and J.D. Laman. Longstanding collaboration with the cooperation AVEBE (Veendam, Groningen) providing protease inhibitors from protein fraction of starch potatoes. The launching company is Eurodrug B.V. (Den Haag) with a cream for diaper dermatitis in healthy infants. This product called Diapocare is now marketed in the entire European Community, and 13 other countries including Thailand, Singapore and Hong Kong.Eurodrug is providing Diapocare also in a compassionate use program for patients, including at UMCG (Depts. Dermatology and Gastroenterology). Eurodrug is currently developing this approach into a medical device for marketing in Europe and the USA. Medical Device Class I status was granted September 2020.

UR - https://diapo-care.com/product/diapo-care-cream/

M3 - Digital or Visual Products

ER -

DiapoCare: Marketed product limiting dermatitis

Abstract

Handle.net

Other files and links

Fingerprint

Effects of potato-derived protease inhibitors on perianal dermatitis after colon resection for long-segment Hirschsprung's disease

Potato tuber proteins efficiently inhibit human faecal proteolytic activity: Implications for treatment of peri-anal dermatitis

Cite this